• news.cision.com/
  • Paxman AB (publ)/
  • PAXMAN publishes newsletter with information on its expanded FDA clearance and newly published, strong clinical results
English

PAXMAN publishes newsletter with information on its expanded FDA clearance and newly published, strong clinical results

Report this content

PAXMAN has today published a new issue of its newsletter aimed at Swedish shareholders, investors and other interested parties. 

This issue highlights the company’s FDA clearance for solid tumours in the USA, the market approval in Mexico, progress in the approval process in Japan and recently published clinical studies where PAXMAN scalp cooling delivered very strong results. In addition to this, CEO Richard Paxman gives his impressions from the company’s attendance at ASCO, the world’s largest oncology conference. 

To read the newsletter (in Swedish only), and to subscribe, follow this link:

http://bit.ly/paxmanjun

PAXMAN’s newsletter, initially published every two months in Swedish, is a part of the company’s effort to strengthen its market communication together with the IR agency Honeybadger. Every published issue of the newsletter will be available on PAXMANs Swedish website,www.paxman.se. The company will be happy to receive requests on topics for upcoming issues as well as other feedback.

For further information, please contact:
Richard Paxman, CEO
Tel: +44 7968 020641
E-mail: richard@paxmanscalpcooling.com
www.paxmanscalpcooling.com

About PAXMAN
 The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With more than 3,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US)

The PAXMAN share is listed on Nasdaq First North. FNCA Sweden AB is the company’s Certified Adviser.

Documents & Links